Brief: Vericel Q4 Gross Margin 77%
14/01/2025 21:05
Jan 14 (Reuters) - Vericel Q4 adjusted EBITDA margin 39%. * outlook FY revenue USD 237-237.5 million
Recent news on Vericel
See all newsMedTech growth concerns likely to overshadow Q3 results, Leerink says
Vericel Corp reports results for the quarter ended June 30 - Earnings Summary
Vericel beats Q2 revenue estimates, boosts annual outlook
Brief: Vericel Q2 EPS USD 0.04
Vericel beats Q1 revenue on MACI, burn care growth, lifts 2026 sales outlook